Articles producció científica> Medicina i Cirurgia

Bempedoic acid. Mechanism of action and pharmacokinetic and pharmacodynamic properties

  • Dades identificatives

    Identificador: imarina:9226474
    Autors:
    Marin, Lluis MasanaGil, Nuria Plana
    Resum:
    Bempedoic acid acts by inhibiting adenosine triphosphate-citrate lyase (ACL) and consequently cholesterol biosynthesis, leading to increased expression of LDL receptors and increasing low-density lipoproteins (LDL-C) plasma clearence. It is a prodrug for oral administration with intracellular activation. It is activatedin liver cells and to a lesser extent in kidney cells, being absent in adipose tissue and muscle cells. Therefore, unlike statins, its potential myotoxic effect is very limited. It has recently been approved as a lipid-lowering drug in combination with diet, with statins, or with other lipid-lowering drugs in patients with hypercholesterolaemia, mixed dyslipidaemia, statin intolerance, or when these are contraindicated. The marketing of bempedoic acid implies, in clinical practice, having a new family of lipid-lowering drugs. (c) 2021 Sociedad Espanola de Arteriosclerosis. Published by Elsevier Espana, S.L.U. All rights reserved.
  • Altres:

    Autor segons l'article: Marin, Lluis Masana; Gil, Nuria Plana;
    Departament: Medicina i Cirurgia
    Autor/s de la URV: Masana Marín, Luis
    Paraules clau: Targets Low-density lipoprotein cholesterol Inhibitor atp citrate lyase Hyperlipidemia Bempedoic acid Atp-citrate lyase Atherosclerosis Activated protein-kinase
    Resum: Bempedoic acid acts by inhibiting adenosine triphosphate-citrate lyase (ACL) and consequently cholesterol biosynthesis, leading to increased expression of LDL receptors and increasing low-density lipoproteins (LDL-C) plasma clearence. It is a prodrug for oral administration with intracellular activation. It is activatedin liver cells and to a lesser extent in kidney cells, being absent in adipose tissue and muscle cells. Therefore, unlike statins, its potential myotoxic effect is very limited. It has recently been approved as a lipid-lowering drug in combination with diet, with statins, or with other lipid-lowering drugs in patients with hypercholesterolaemia, mixed dyslipidaemia, statin intolerance, or when these are contraindicated. The marketing of bempedoic acid implies, in clinical practice, having a new family of lipid-lowering drugs. (c) 2021 Sociedad Espanola de Arteriosclerosis. Published by Elsevier Espana, S.L.U. All rights reserved.
    Àrees temàtiques: Pharmacology (medical) Peripheral vascular disease Medicina iii Medicina i Cardiology and cardiovascular medicine
    Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
    Adreça de correu electrònic de l'autor: luis.masana@urv.cat
    Identificador de l'autor: 0000-0002-0789-4954
    Data d'alta del registre: 2024-07-27
    Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
    Enllaç font original: https://www.sciencedirect.com/science/article/pii/S0214916821000462?via%3Dihub
    URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referència a l'article segons font original: Clinica E Investigacion En Arteriosclerosis. 33 53-57
    Referència de l'ítem segons les normes APA: Marin, Lluis Masana; Gil, Nuria Plana; (2021). Bempedoic acid. Mechanism of action and pharmacokinetic and pharmacodynamic properties. Clinica E Investigacion En Arteriosclerosis, 33(), 53-57. DOI: 10.1016/j.arteri.2021.02.012
    DOI de l'article: 10.1016/j.arteri.2021.02.012
    Entitat: Universitat Rovira i Virgili
    Any de publicació de la revista: 2021
    Tipus de publicació: Journal Publications
  • Paraules clau:

    Cardiology and Cardiovascular Medicine,Peripheral Vascular Disease,Pharmacology (Medical)
    Targets
    Low-density lipoprotein cholesterol
    Inhibitor atp citrate lyase
    Hyperlipidemia
    Bempedoic acid
    Atp-citrate lyase
    Atherosclerosis
    Activated protein-kinase
    Pharmacology (medical)
    Peripheral vascular disease
    Medicina iii
    Medicina i
    Cardiology and cardiovascular medicine
  • Documents:

  • Cerca a google

    Search to google scholar